Stellar data comes late in life for weight-loss drug

28 August 2018

It is not unexpected to see mainstream media giving coverage to data showing potential in a drug that could be a big player in the fight against obesity in middle-aged people.

What is unusual is that the drug concerned, Belviq (lorcaserin HCl) is hardly in the first flushes of youth, having received US Food and Drug Administration (FDA) approval more than two years ago.

The news has emerged now as data from the Eisai (TYO: 4523) drug has been presented at the European Society of Cardiology (ESC) Congress 2018 and concurrently published in the New England Journal of Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK